

### **New insights about inflammation's role in causing heart diseases**

Scientists have stressed that addressing chronic inflammation is vital in preventing heart disease. A 2017 study found that the Novartis-made drug canakinumab (Ilaris), which targets a specific molecule involved in inflammation known as interleukin-1, cut the risk of heart attacks, strokes, and other cardiovascular events by 17% in people with heart disease who were already taking standard heart medications.